Agoraphobia

Psychiatric MONDO:0003709 Pathograph 12 Show in embeddings browser Anxiety Disorder Mental Health Disorder

Agoraphobia is a phobic anxiety disorder characterized by marked fear or anxiety about situations such as public transport, open spaces, enclosed places, crowds or queues, and being outside the home alone, arising from the thought that escape might be difficult or help unavailable should panic-like or other incapacitating symptoms occur. DSM-5 and ICD-11 established agoraphobia as a diagnosis independent of panic disorder rather than a residual panic disorder specifier. Two partly separable mechanistic strands are described: a fear-learning strand in which heightened startle and fear-network reactivity support catastrophic agoraphobic cognitions, and a spatial-orientation strand in which vestibular dysfunction drives a compensatory dependence on visual and proprioceptive cues, producing discomfort precisely in the settings where those cues are unreliable.

Ask OpenScientist

Ask a research question about Agoraphobia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
4
Phenotypes
12
Pathograph
2
Genes
2
Medical Actions
3
Differentials
1
Models
8
References
1
Deep Research
👪

Inheritance

1
Polygenic susceptibility HP:0010982
Agoraphobia is heritable but polygenic. Twin modelling of DSM-IV phobias in women estimated heritability between 0.43 and 0.63, with agoraphobia loading on a liability factor shared with social phobia rather than with the simple phobias.
Polygenic inheritance
Show evidence (2 references)
PMID:21211096 SUPPORT Human Clinical
"In the best fitting twin model, which did not include shared environmental factors, heritability estimates for the phobias ranged from 0.43 to 0.63."
Population-based twin study quantifies the heritable component across the phobias including agoraphobia.
PMID:21211096 SUPPORT Human Clinical
"The second liability factor strongly influenced the complex phobias, but also loaded weak to moderate on all the other phobias."
Supports agoraphobia grouping with social phobia on a shared complex phobia liability factor rather than with the simple phobias.
⚙

Pathophysiology

7
GLRB Glycine Receptor Variation
Non-coding variants in GLRB, encoding the glycine receptor beta subunit, are associated with agoraphobic cognitions at genome-wide significance in a dimensional phenotype based on the Agoraphobia Cognition Questionnaire, and replicate against dichotomous and categorical agoraphobia phenotypes. The same gene carries rare coding mutations causing hyperekplexia, a neurological startle disorder with agoraphobic behavior.
Animal models
Partial Glrb knockout mouse Mouse partially recapitulates Reduced Glrb dosage in mouse models the direction of effect proposed for the human non-coding risk variants.
Downstream
Exaggerated Startle and Fear Network Activation
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"We followed up on this finding in a larger dimensional ACQ sample (N=2547) and in independent samples with a dichotomous AG phenotype based on the Symptoms Checklist (SCL-90; N=3845) and a case-control sample with the categorical phenotype PD/AG (Ncombined =1012) obtaining highly significant..."
Replication across dimensional, dichotomous and categorical agoraphobia phenotypes supports the GLRB association.
Exaggerated Startle and Fear Network Activation
Carriers of GLRB risk variants show an increased startle reflex and increased fear-network and general sensory activation, an intermediate phenotype linking the genetic finding to the clinical fear response.
startle response GO:0001964 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased startle response (GO:0001964). GO:0001964 is a biological process from the Gene Ontology. ↑ INCREASED
amygdala UBERON:0001876 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in amygdala (UBERON:0001876). UBERON:0001876 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Agoraphobic Cognitions Heightened startle and fear-network reactivity is proposed to support catastrophic appraisal of bodily sensations in agoraphobic situations.
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"Analyses of intermediate PD/AG phenotypes demonstrated increased startle reflex and increased fear network, as well as general sensory activation by GLRB risk gene variants rs78726293, rs191260602, rs17035816 and rs7688285."
Reports the startle and fear-network activation phenotype this node describes.
Vestibular Dysfunction
Peripheral and central vestibular abnormalities are over-represented in agoraphobia and in panic disorder with agoraphobia, and are the proposed initiating lesion of the spatial-orientation strand of the disorder.
vestibular system UBERON:0004681 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vestibular system (UBERON:0004681). UBERON:0004681 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Non-Vestibular Balance Control Strategy
Show evidence (1 reference)
PMID:18653552 SUPPORT Human Clinical
"The presence of either panic attacks or fear of heights increased the probability of having caloric hypofunction in a non-additive fashion."
Caloric hypofunction indicates peripheral vestibular dysfunction and is associated with the anxiety phenomenology relevant to agoraphobia.
Non-Vestibular Balance Control Strategy
Agoraphobic patients compensate by relying on proprioceptive and visual spatial cues rather than vestibular input for upright balance. On computerized dynamic posturography this shows as surface dependence, impaired balance specifically when proprioceptive information is degraded.
Downstream
Space and Motion Discomfort
Show evidence (1 reference)
PMID:9178344 SUPPORT Human Clinical
"The agoraphobics had impaired balance when proprioceptive balance information was minimized by sway-referencing the support surface (p < 0.02)."
Posturography directly demonstrates the surface dependence this node describes, in an agoraphobic group specifically.
Space and Motion Discomfort
Discomfort in environments providing inadequate or conflicting visual and proprioceptive spatial reference. This is the mechanistic bridge to the specific situational content of agoraphobia, since open spaces, crowds and moving vehicles are exactly the settings in which such cues are degraded.
Downstream
Situational Fear and Avoidance
Show evidence (2 references)
PMID:18653552 SUPPORT Human Clinical
"SMD and anxiety responses were independently associated with abnormal balance."
Establishes space and motion discomfort as a measurable construct tied to objectively abnormal balance, independent of anxiety response.
PMID:18653552 SUPPORT Human Clinical
"In patients with anxiety disorders, higher SMD is indicative of somatosensory dependence in the control of balance."
Connects the discomfort construct back to the somatosensory dependence of the upstream node.
Agoraphobic Cognitions
Catastrophic beliefs that escape would be difficult or help unavailable if incapacitating symptoms occurred. These cognitions are the phenotype on which the GLRB genome-wide association was defined, via the Agoraphobia Cognition Questionnaire.
Downstream
Situational Fear and Avoidance
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1."
Establishes agoraphobic cognitions as an operationalized, measurable dimensional phenotype.
Situational Fear and Avoidance
The convergent clinical endpoint: fear of, and active avoidance of, the agoraphobic situations. Avoidance is the feature that drives the disorder's course and functional impact, and is the primary target of treatment.
Downstream
Agoraphobia
Anxiety
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Agoraphobia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Ear 1
Abnormal vestibular function HP:0001751 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal vestibular function (HP:0001751). HP:0001751 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9178344 SUPPORT Human Clinical
"The agoraphobics had impaired balance when proprioceptive balance information was minimized by sway-referencing the support surface (p < 0.02)."
Objective posturographic abnormality measured in an agoraphobic group.
Nervous System 3
Agoraphobia HP:0000756 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Agoraphobia (HP:0000756). HP:0000756 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20143426 SUPPORT Human Clinical
"We come to the conclusion that AG should be conceptualized as an independent disorder with more specific criteria rather than a subordinate, residual form of PD as currently stipulated in DSM-IV-TR."
Review establishing agoraphobia as an independent diagnostic entity, the basis for curating it as its own disease rather than a panic disorder specifier.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33849246 SUPPORT Human Clinical
"Current nosology redefined agoraphobia as an autonomous diagnosis distinct from panic disorder."
Community survey of agoraphobia as an anxiety diagnosis in its own right; the anxiety phenotype itself is definitional.
Exaggerated startle response HP:0002267 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exaggerated startle response (HP:0002267). HP:0002267 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"In conjunction with the clinical observation that rare coding GLRB gene mutations are associated with the neurological disorder hyperekplexia characterized by a generalized startle reaction and agoraphobic behavior, our data provide evidence that non-coding, although functional GLRB gene..."
Links the startle phenotype to GLRB variation and to agoraphobic behavior.
🧬

Genetic Associations

2
GLRB
Gene: GLRB hgnc:4329 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GLRB (hgnc:4329). hgnc:4329 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"GLRB gene expression was found to be modulated by rs7688285 in brain tissue, as well as cell culture."
Provides the functional basis for treating these non-coding variants as acting through GLRB expression.
TMEM132D
Gene: TMEM132D hgnc:29411 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TMEM132D (hgnc:29411). hgnc:29411 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:22948381 SUPPORT INDIRECT Human Clinical
"The present results support the initial finding that TMEM132D gene contributes to genetic susceptibility for PD in individuals of EA"
A replication and meta-analysis confirms TMEM132D as a susceptibility locus for panic disorder with agoraphobia; INDIRECT because the sample is panic-disorder-derived rather than agoraphobia-specific.
💊

Medical Actions

2
Exposure in vivo combined with antidepressant pharmacotherapy
Action: behavioral intervention with exposure in vivoNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is behavioral intervention with exposure in vivo, annotated with Behavioral Intervention (NCIT:C15184). NCIT:C15184 is a clinical intervention from the NCI Thesaurus. Ontology label: Behavioral Intervention NCIT:C15184
Platform: Behavioral / lifestyle
In a meta-analysis of 106 studies of panic disorder with or without agoraphobia, every active treatment examined outperformed control on the agoraphobic avoidance outcome specifically, and the combination of antidepressants with exposure in vivo was superior to all other conditions for that outcome.
Mechanism Target:
Situational Fear and Avoidance — Exposure directly targets the avoidance endpoint of the causal chain.
Target Phenotypes: Agoraphobia HP:0000756 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Agoraphobia (HP:0000756). HP:0000756 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:9284865 SUPPORT Human Clinical
"With regard to agoraphobic avoidance, all seven treatments were superior to the control condition."
Meta-analysis reports agoraphobic avoidance as a distinct outcome, so this supports treatment of agoraphobia specifically rather than of panic attacks.
PMID:9284865 SUPPORT Human Clinical
"For agoraphobic avoidance, the combination of antidepressants with exposure in vivo was superior to the other conditions."
Identifies the superior combination specifically for the agoraphobic avoidance outcome.
Antidepressant pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: selective serotonin reuptake inhibitor NCIT:C94725 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses selective serotonin reuptake inhibitor (NCIT:C94725). NCIT:C94725 is a therapeutic agent from the NCI Thesaurus.
Platform: Small molecule
Antidepressants are effective for panic disorder with or without agoraphobia and improve agoraphobic avoidance, though the network meta-analytic evidence base is defined on panic disorder populations.
Target Phenotypes: Agoraphobia HP:0000756 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Agoraphobia (HP:0000756). HP:0000756 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9284865 SUPPORT INDIRECT Human Clinical
"Antidepressants, psychological panic management, high-potency benzodiazepines, and antidepressants combined with exposure in vivo were superior to the control condition for panic attacks."
This sentence reports the panic-attack outcome rather than the agoraphobia outcome, so it supports pharmacotherapy for agoraphobia only through the inference that treating the panic component reduces agoraphobic avoidance; graded indirect for that reason.
🔬

Diagnosis

1
Clinical assessment for agoraphobic fear and avoidance (Diagnosis is clinical, requiring marked fear or anxiety about two or more of the five DSM-5 situational clusters, arising from thoughts that escape might be difficult or help unavailable if incapacitating symptoms occurred, with active avoidance, persistence over time, and impairment. The Agoraphobia Cognition Questionnaire is the standard dimensional research instrument.)
Show evidence (1 reference)
PMID:28167838 SUPPORT Human Clinical
"We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1."
Identifies the standard dimensional instrument for agoraphobic cognitions.
📊

Prevalence

1
Italian adult community sample
Lifetime Prevalence 1500.0 per 100,000 >1 in 1,000
Community survey of 2338 randomly selected adults interviewed by clinicians with the ANTAS schedule against ICD-10 criteria; prevalence was higher in women (2.0%) than men (0.9%).
Show evidence (1 reference)
PMID:33849246 SUPPORT Human Clinical
"One out of seventy people may suffer from agoraphobia in their lifetime."
Clinician-administered community survey supplies a lifetime prevalence estimate for agoraphobia as an autonomous diagnosis.
⚖️

Clinical Burden

Moderate
Health-related quality of life in agoraphobia is reduced to a degree comparable with major depression, PTSD and obsessive-compulsive disorder, and the reduction is similar whether or not panic disorder is also present.
Show evidence (1 reference)
PMID:33849246 SUPPORT Human Clinical
"The attributable burden in terms of HR-QoL is substantial and comparable to the one observed for chronic mental disorders such as major depression, post-traumatic stress disorder, or obsessive-compulsive disorder."
Quantified quality-of-life comparison establishes the burden level.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Agoraphobia:

Panic disorder MONDO:0005383
Overlapping Features Panic disorder is defined by recurrent unexpected panic attacks and concern about further attacks. Agoraphobia frequently co-occurs with it but can exist independently, which is why current nosology separates the two.
Show evidence (1 reference)
PMID:33849246 SUPPORT Human Clinical
"Agoraphobia was more often seen among those with (n=26; 1.1%) than without (n=9; 0.4%) panic disorder: OR=8.3; 2.9-24.4."
Quantifies the association with panic disorder while documenting cases occurring without it.
Social anxiety disorder MONDO:0001247
Overlapping Features In social anxiety disorder the feared outcome is negative social evaluation, whereas in agoraphobia it is difficulty escaping or obtaining help if incapacitating symptoms occur.
Specific phobia Not Yet Curated MONDO:0012000
Overlapping Features Specific phobia is fear of a circumscribed object or situation; agoraphobia requires fear across two or more distinct situational clusters.
🐁

Animal Models

1
Partial Glrb knockout mouse
Mice with partial knockout of Glrb, the mouse orthologue of the human agoraphobia-associated gene, were reported to display an agoraphobic behavioral phenotype, supporting the translational relevance of the human genetic association.
Species
Mouse
Genotype
Partial Glrb knockout
Publication
PMID:28167838
Pathograph links
GLRB Glycine Receptor Variation partially recapitulates fidelity: low observes: organism Reduced Glrb dosage in mouse models the direction of effect proposed for the human non-coding risk variants.
Limitations: The human association is with non-coding regulatory variants producing modest expression differences, whereas the model is a partial gene knockout, so the perturbation is not equivalent in kind or magnitude. Agoraphobia is defined by situational cognitions about escape and help availability, which have no faithful murine counterpart, so the reported agoraphobic phenotype is an avoidance-behavior analogue. The finding is reported as one component of a larger human genetics paper rather than as a dedicated behavioral study.
Show evidence (1 reference)
PMID:28167838 SUPPORT Model Organism
"Partial Glrb knockout mice demonstrated an agoraphobic phenotype."
Reports the animal-model result supporting a causal role for reduced GLRB function.
{ }

Source YAML

click to show 
name: Agoraphobia
creation_date: "2026-09-07T15:00:00Z"
category: Psychiatric
description: >-
  Agoraphobia is a phobic anxiety disorder characterized by marked fear or
  anxiety about situations such as public transport, open spaces, enclosed
  places, crowds or queues, and being outside the home alone, arising from the
  thought that escape might be difficult or help unavailable should
  panic-like or other incapacitating symptoms occur. DSM-5 and ICD-11
  established agoraphobia as a diagnosis independent of panic disorder rather
  than a residual panic disorder specifier. Two partly separable mechanistic
  strands are described: a fear-learning strand in which heightened startle
  and fear-network reactivity support catastrophic agoraphobic cognitions, and
  a spatial-orientation strand in which vestibular dysfunction drives a
  compensatory dependence on visual and proprioceptive cues, producing
  discomfort precisely in the settings where those cues are unreliable.
disease_term:
  preferred_term: agoraphobia
  term:
    id: MONDO:0003709
    label: agoraphobia
parents:
- Anxiety Disorder
- Mental Health Disorder
references:
- reference: PMID:20143426
  title: "Agoraphobia: a review of the diagnostic classificatory position and criteria."
- reference: PMID:28167838
  title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
- reference: PMID:22948381
  title: "Replication and meta-analysis of TMEM132D gene variants in panic disorder."
- reference: PMID:21211096
  title: "The structure of genetic and environmental risk factors for phobias in women."
- reference: PMID:18653552
  title: "Space and motion discomfort and abnormal balance control in patients with anxiety disorders."
- reference: PMID:9178344
  title: "Surface dependence: a balance control strategy in panic disorder with agoraphobia."
- reference: PMID:9284865
  title: "A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments."
- reference: PMID:33849246
  title: "The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy."
prevalence:
- population: Italian adult community sample
  measure_type: LIFETIME_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1500.0
  rate_denominator: POPULATION
  notes: >-
    Community survey of 2338 randomly selected adults interviewed by clinicians
    with the ANTAS schedule against ICD-10 criteria; prevalence was higher in
    women (2.0%) than men (0.9%).
  evidence:
  - reference: PMID:33849246
    reference_title: "The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One out of seventy people may suffer from agoraphobia in their lifetime.
    explanation: >-
      Clinician-administered community survey supplies a lifetime prevalence
      estimate for agoraphobia as an autonomous diagnosis.
clinical_burden:
  burden_level: MODERATE
  rationale: >-
    Health-related quality of life in agoraphobia is reduced to a degree
    comparable with major depression, PTSD and obsessive-compulsive disorder,
    and the reduction is similar whether or not panic disorder is also present.
  evidence:
  - reference: PMID:33849246
    reference_title: "The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The attributable burden in terms of HR-QoL is substantial and comparable
      to the one observed for chronic mental disorders such as major
      depression, post-traumatic stress disorder, or obsessive-compulsive
      disorder.
    explanation: >-
      Quantified quality-of-life comparison establishes the burden level.
pathophysiology:
- name: GLRB Glycine Receptor Variation
  description: >-
    Non-coding variants in GLRB, encoding the glycine receptor beta subunit,
    are associated with agoraphobic cognitions at genome-wide significance in a
    dimensional phenotype based on the Agoraphobia Cognition Questionnaire, and
    replicate against dichotomous and categorical agoraphobia phenotypes. The
    same gene carries rare coding mutations causing hyperekplexia, a
    neurological startle disorder with agoraphobic behavior.
  biological_scale: MOLECULAR
  downstream:
  - target: Exaggerated Startle and Fear Network Activation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28167838
      reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Analyses of intermediate PD/AG phenotypes demonstrated increased
        startle reflex and increased fear network, as well as general sensory
        activation by GLRB risk gene variants rs78726293, rs191260602,
        rs17035816 and rs7688285.
      explanation: >-
        Directly links the risk variants named by this node to the startle and
        fear-network intermediate phenotypes of the downstream node, which is
        the edge rather than either node alone.
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We followed up on this finding in a larger dimensional ACQ sample
      (N=2547) and in independent samples with a dichotomous AG phenotype based
      on the Symptoms Checklist (SCL-90; N=3845) and a case-control sample with
      the categorical phenotype PD/AG (Ncombined =1012) obtaining highly
      significant P-values also for GLRB single-nucleotide variants rs17035816
      (P=3.8 × 10-4) and rs7688285 (P=7.6 × 10-5).
    explanation: >-
      Replication across dimensional, dichotomous and categorical agoraphobia
      phenotypes supports the GLRB association.
- name: Exaggerated Startle and Fear Network Activation
  description: >-
    Carriers of GLRB risk variants show an increased startle reflex and
    increased fear-network and general sensory activation, an intermediate
    phenotype linking the genetic finding to the clinical fear response.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: startle response
    modifier: INCREASED
    term:
      id: GO:0001964
      label: startle response
  locations:
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  downstream:
  - target: Agoraphobic Cognitions
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Heightened startle and fear-network reactivity is proposed to support
      catastrophic appraisal of bodily sensations in agoraphobic situations.
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analyses of intermediate PD/AG phenotypes demonstrated increased startle
      reflex and increased fear network, as well as general sensory activation
      by GLRB risk gene variants rs78726293, rs191260602, rs17035816 and
      rs7688285.
    explanation: >-
      Reports the startle and fear-network activation phenotype this node
      describes.
- name: Vestibular Dysfunction
  description: >-
    Peripheral and central vestibular abnormalities are over-represented in
    agoraphobia and in panic disorder with agoraphobia, and are the proposed
    initiating lesion of the spatial-orientation strand of the disorder.
  biological_scale: TISSUE
  locations:
  - preferred_term: vestibular system
    term:
      id: UBERON:0004681
      label: vestibular system
  downstream:
  - target: Non-Vestibular Balance Control Strategy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:9178344
      reference_title: "Surface dependence: a balance control strategy in panic disorder with agoraphobia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Vestibular dysfunction may lead to an information processing strategy
        focusing on spatial stimuli from two nonvestibular sensory channels,
        vision and proprioception.
      explanation: >-
        States the proposed causal step from vestibular dysfunction to the
        compensatory non-vestibular strategy, which is this edge.
  evidence:
  - reference: PMID:18653552
    reference_title: "Space and motion discomfort and abnormal balance control in patients with anxiety disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of either panic attacks or fear of heights increased the
      probability of having caloric hypofunction in a non-additive fashion.
    explanation: >-
      Caloric hypofunction indicates peripheral vestibular dysfunction and is
      associated with the anxiety phenomenology relevant to agoraphobia.
- name: Non-Vestibular Balance Control Strategy
  description: >-
    Agoraphobic patients compensate by relying on proprioceptive and visual
    spatial cues rather than vestibular input for upright balance. On
    computerized dynamic posturography this shows as surface dependence,
    impaired balance specifically when proprioceptive information is degraded.
  biological_scale: ORGANISM
  downstream:
  - target: Space and Motion Discomfort
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:9178344
      reference_title: "Surface dependence: a balance control strategy in panic disorder with agoraphobia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Agoraphobics rely on proprioceptive cues for maintenance of upright
        balance. This strategy may lead to intolerance of situations
        characterized by unstable support.
      explanation: >-
        The authors state the step from the compensatory balance strategy to
        situational intolerance, which is this edge.
  evidence:
  - reference: PMID:9178344
    reference_title: "Surface dependence: a balance control strategy in panic disorder with agoraphobia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The agoraphobics had impaired balance when proprioceptive balance
      information was minimized by sway-referencing the support surface (p <
      0.02).
    explanation: >-
      Posturography directly demonstrates the surface dependence this node
      describes, in an agoraphobic group specifically.
- name: Space and Motion Discomfort
  description: >-
    Discomfort in environments providing inadequate or conflicting visual and
    proprioceptive spatial reference. This is the mechanistic bridge to the
    specific situational content of agoraphobia, since open spaces, crowds and
    moving vehicles are exactly the settings in which such cues are degraded.
  biological_scale: ORGANISM
  downstream:
  - target: Situational Fear and Avoidance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:18653552
    reference_title: "Space and motion discomfort and abnormal balance control in patients with anxiety disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SMD and anxiety responses were independently associated with abnormal
      balance.
    explanation: >-
      Establishes space and motion discomfort as a measurable construct tied to
      objectively abnormal balance, independent of anxiety response.
  - reference: PMID:18653552
    reference_title: "Space and motion discomfort and abnormal balance control in patients with anxiety disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients with anxiety disorders, higher SMD is indicative of
      somatosensory dependence in the control of balance.
    explanation: >-
      Connects the discomfort construct back to the somatosensory dependence of
      the upstream node.
- name: Agoraphobic Cognitions
  description: >-
    Catastrophic beliefs that escape would be difficult or help unavailable if
    incapacitating symptoms occurred. These cognitions are the phenotype on
    which the GLRB genome-wide association was defined, via the Agoraphobia
    Cognition Questionnaire.
  biological_scale: ORGANISM
  downstream:
  - target: Situational Fear and Avoidance
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We therefore performed a genome-wide association study with a
      dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia
      Cognition Questionnaire (ACQ) in a sample of 1370 healthy German
      volunteers of the CRC TRR58 MEGA study wave 1.
    explanation: >-
      Establishes agoraphobic cognitions as an operationalized, measurable
      dimensional phenotype.
- name: Situational Fear and Avoidance
  description: >-
    The convergent clinical endpoint: fear of, and active avoidance of, the
    agoraphobic situations. Avoidance is the feature that drives the disorder's
    course and functional impact, and is the primary target of treatment.
  biological_scale: ORGANISM
  downstream:
  - target: Agoraphobia
  - target: Anxiety
phenotypes:
- name: Agoraphobia
  category: Behavioral
  description: >-
    Fear and avoidance of situations where escape might be difficult or help
    unavailable, in two or more of the DSM-5 situational clusters.
  phenotype_term:
    preferred_term: Agoraphobia
    term:
      id: HP:0000756
      label: Agoraphobia
  evidence:
  - reference: PMID:20143426
    reference_title: "Agoraphobia: a review of the diagnostic classificatory position and criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We come to the conclusion that AG should be conceptualized as an
      independent disorder with more specific criteria rather than a
      subordinate, residual form of PD as currently stipulated in DSM-IV-TR.
    explanation: >-
      Review establishing agoraphobia as an independent diagnostic entity, the
      basis for curating it as its own disease rather than a panic disorder
      specifier.
- name: Anxiety
  category: Behavioral
  description: >-
    Marked anticipatory anxiety about entering or remaining in agoraphobic
    situations.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:33849246
    reference_title: "The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Current nosology redefined agoraphobia as an autonomous diagnosis
      distinct from panic disorder.
    explanation: >-
      Community survey of agoraphobia as an anxiety diagnosis in its own right;
      the anxiety phenotype itself is definitional.
- name: Exaggerated startle response
  category: Clinical Sign
  description: >-
    Increased startle reflex is an intermediate phenotype associated with GLRB
    risk variants, and generalized startle is the cardinal feature of
    hyperekplexia, caused by rare coding mutations in the same gene.
  phenotype_term:
    preferred_term: Exaggerated startle response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In conjunction with the clinical observation that rare coding GLRB gene
      mutations are associated with the neurological disorder hyperekplexia
      characterized by a generalized startle reaction and agoraphobic behavior,
      our data provide evidence that non-coding, although functional GLRB gene
      polymorphisms may predispose to PD by increasing startle response and
      agoraphobic cognitions.
    explanation: >-
      Links the startle phenotype to GLRB variation and to agoraphobic
      behavior.
- name: Abnormal vestibular function
  category: Clinical Sign
  description: >-
    Balance and vestibular test abnormalities, particularly surface-dependent
    balance control, are over-represented in agoraphobia.
  phenotype_term:
    preferred_term: Abnormal vestibular function
    term:
      id: HP:0001751
      label: Abnormal vestibular function
  evidence:
  - reference: PMID:9178344
    reference_title: "Surface dependence: a balance control strategy in panic disorder with agoraphobia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The agoraphobics had impaired balance when proprioceptive balance
      information was minimized by sway-referencing the support surface (p <
      0.02).
    explanation: >-
      Objective posturographic abnormality measured in an agoraphobic group.
genetic:
- name: GLRB
  notes: >-
    Non-coding GLRB variants are associated with agoraphobic cognitions and
    with increased startle and fear-network activation. These are common
    susceptibility polymorphisms under a complex-trait model, not Mendelian
    causal variants.
  gene_term:
    preferred_term: GLRB
    term:
      id: hgnc:4329
      label: GLRB
  relationship_type: SUSCEPTIBILITY
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GLRB gene expression was found to be modulated by rs7688285 in brain
      tissue, as well as cell culture.
    explanation: >-
      Provides the functional basis for treating these non-coding variants as
      acting through GLRB expression.
- name: TMEM132D
  notes: >-
    TMEM132D is the most replicated candidate susceptibility gene for panic
    disorder with agoraphobia. As with GLRB, the replicated association is
    derived from panic-disorder samples in which agoraphobia is a modifier
    rather than from an agoraphobia-only cohort, so the binding carries
    directness: INDIRECT.
  gene_term:
    preferred_term: TMEM132D
    term:
      id: hgnc:29411
      label: TMEM132D
  relationship_type: SUSCEPTIBILITY
  evidence:
  - reference: PMID:22948381
    reference_title: "Replication and meta-analysis of TMEM132D gene variants in panic disorder."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The present results support the initial finding that TMEM132D gene
      contributes to genetic susceptibility for PD in individuals of EA
    explanation: >-
      A replication and meta-analysis confirms TMEM132D as a susceptibility
      locus for panic disorder with agoraphobia; INDIRECT because the sample is
      panic-disorder-derived rather than agoraphobia-specific.
inheritance:
- name: Polygenic susceptibility
  description: >-
    Agoraphobia is heritable but polygenic. Twin modelling of DSM-IV phobias in
    women estimated heritability between 0.43 and 0.63, with agoraphobia
    loading on a liability factor shared with social phobia rather than with
    the simple phobias.
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  evidence:
  - reference: PMID:21211096
    reference_title: "The structure of genetic and environmental risk factors for phobias in women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the best fitting twin model, which did not include shared
      environmental factors, heritability estimates for the phobias ranged from
      0.43 to 0.63.
    explanation: >-
      Population-based twin study quantifies the heritable component across the
      phobias including agoraphobia.
  - reference: PMID:21211096
    reference_title: "The structure of genetic and environmental risk factors for phobias in women."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second liability factor strongly influenced the complex phobias, but
      also loaded weak to moderate on all the other phobias.
    explanation: >-
      Supports agoraphobia grouping with social phobia on a shared complex
      phobia liability factor rather than with the simple phobias.
animal_models:
- name: Partial Glrb knockout mouse
  species: Mouse
  genotype: Partial Glrb knockout
  publication: PMID:28167838
  description: >-
    Mice with partial knockout of Glrb, the mouse orthologue of the human
    agoraphobia-associated gene, were reported to display an agoraphobic
    behavioral phenotype, supporting the translational relevance of the human
    genetic association.
  modeled_mechanisms:
  - target: GLRB Glycine Receptor Variation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      Reduced Glrb dosage in mouse models the direction of effect proposed for
      the human non-coding risk variants.
    limitations: >-
      The human association is with non-coding regulatory variants producing
      modest expression differences, whereas the model is a partial gene
      knockout, so the perturbation is not equivalent in kind or magnitude.
      Agoraphobia is defined by situational cognitions about escape and help
      availability, which have no faithful murine counterpart, so the reported
      agoraphobic phenotype is an avoidance-behavior analogue. The finding is
      reported as one component of a larger human genetics paper rather than as
      a dedicated behavioral study.
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Partial Glrb knockout mice demonstrated an agoraphobic phenotype.
    explanation: >-
      Reports the animal-model result supporting a causal role for reduced GLRB
      function.
diagnosis:
- name: Clinical assessment for agoraphobic fear and avoidance
  presence: >-
    Diagnosis is clinical, requiring marked fear or anxiety about two or more
    of the five DSM-5 situational clusters, arising from thoughts that escape
    might be difficult or help unavailable if incapacitating symptoms occurred,
    with active avoidance, persistence over time, and impairment. The
    Agoraphobia Cognition Questionnaire is the standard dimensional research
    instrument.
  evidence:
  - reference: PMID:28167838
    reference_title: "GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We therefore performed a genome-wide association study with a
      dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia
      Cognition Questionnaire (ACQ) in a sample of 1370 healthy German
      volunteers of the CRC TRR58 MEGA study wave 1.
    explanation: >-
      Identifies the standard dimensional instrument for agoraphobic
      cognitions.
differential_diagnoses:
- name: Panic disorder
  description: >-
    Panic disorder is defined by recurrent unexpected panic attacks and concern
    about further attacks. Agoraphobia frequently co-occurs with it but can
    exist independently, which is why current nosology separates the two.
  disease_term:
    preferred_term: panic disorder
    term:
      id: MONDO:0005383
      label: panic disorder
  evidence:
  - reference: PMID:33849246
    reference_title: "The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Agoraphobia was more often seen among those with (n=26; 1.1%) than
      without (n=9; 0.4%) panic disorder: OR=8.3; 2.9-24.4.
    explanation: >-
      Quantifies the association with panic disorder while documenting cases
      occurring without it.
- name: Social anxiety disorder
  description: >-
    In social anxiety disorder the feared outcome is negative social
    evaluation, whereas in agoraphobia it is difficulty escaping or obtaining
    help if incapacitating symptoms occur.
  disease_term:
    preferred_term: social anxiety disorder
    term:
      id: MONDO:0001247
      label: social phobia
- name: Specific phobia
  description: >-
    Specific phobia is fear of a circumscribed object or situation; agoraphobia
    requires fear across two or more distinct situational clusters.
  disease_term:
    preferred_term: specific phobia
    term:
      id: MONDO:0012000
      label: specific phobia
treatments:
- name: Exposure in vivo combined with antidepressant pharmacotherapy
  description: >-
    In a meta-analysis of 106 studies of panic disorder with or without
    agoraphobia, every active treatment examined outperformed control on the
    agoraphobic avoidance outcome specifically, and the combination of
    antidepressants with exposure in vivo was superior to all other conditions
    for that outcome.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral intervention with exposure in vivo
    term:
      id: NCIT:C15184
      label: Behavioral Intervention
  target_mechanisms:
  - target: Situational Fear and Avoidance
    description: >-
      Exposure directly targets the avoidance endpoint of the causal chain.
  target_phenotypes:
  - preferred_term: Agoraphobia
    term:
      id: HP:0000756
      label: Agoraphobia
  evidence:
  - reference: PMID:9284865
    reference_title: "A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With regard to agoraphobic avoidance, all seven treatments were superior
      to the control condition.
    explanation: >-
      Meta-analysis reports agoraphobic avoidance as a distinct outcome, so
      this supports treatment of agoraphobia specifically rather than of panic
      attacks.
  - reference: PMID:9284865
    reference_title: "A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For agoraphobic avoidance, the combination of antidepressants with
      exposure in vivo was superior to the other conditions.
    explanation: >-
      Identifies the superior combination specifically for the agoraphobic
      avoidance outcome.
  notes: >-
    The trial literature is overwhelmingly conducted in panic disorder with or
    without agoraphobia rather than in agoraphobia as an independent diagnosis.
    This meta-analysis is cited because it reports agoraphobic avoidance as a
    separate outcome variable; it is not evidence from an agoraphobia-only
    population.
- name: Antidepressant pharmacotherapy
  description: >-
    Antidepressants are effective for panic disorder with or without
    agoraphobia and improve agoraphobic avoidance, though the network
    meta-analytic evidence base is defined on panic disorder populations.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: selective serotonin reuptake inhibitor
      term:
        id: NCIT:C94725
        label: Selective Serotonin Reuptake Inhibitor
  target_phenotypes:
  - preferred_term: Agoraphobia
    term:
      id: HP:0000756
      label: Agoraphobia
  evidence:
  - reference: PMID:9284865
    reference_title: "A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antidepressants, psychological panic management, high-potency
      benzodiazepines, and antidepressants combined with exposure in vivo were
      superior to the control condition for panic attacks.
    explanation: >-
      This sentence reports the panic-attack outcome rather than the
      agoraphobia outcome, so it supports pharmacotherapy for agoraphobia only
      through the inference that treating the panic component reduces
      agoraphobic avoidance; graded indirect for that reason.
notes: >-
  Curated from primary literature located through PubMed. The most important
  interpretive caution for this entry is that the great majority of agoraphobia
  research is conducted in panic disorder samples with agoraphobia as a
  modifier, even though current nosology treats agoraphobia as independent.
  Evidence has therefore been selected preferentially where the source reports
  an agoraphobia-specific outcome, phenotype or sample, and treatment evidence
  is annotated where it does not. The two mechanistic strands curated here, the
  GLRB startle/fear-network strand and the vestibular/space-and-motion
  discomfort strand, are not established as acting in the same patients; they
  are curated as parallel routes converging on situational avoidance rather
  than as a single validated pathway. The posturography studies are small and
  date from the 1990s.
📚

References & Deep Research

References

8
PMID:20143426
Agoraphobia: a review of the diagnostic classificatory position and criteria.
No top-level findings curated for this source.
PMID:28167838
GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder.
No top-level findings curated for this source.
PMID:22948381
Replication and meta-analysis of TMEM132D gene variants in panic disorder.
No top-level findings curated for this source.
PMID:21211096
The structure of genetic and environmental risk factors for phobias in women.
No top-level findings curated for this source.
PMID:18653552
Space and motion discomfort and abnormal balance control in patients with anxiety disorders.
No top-level findings curated for this source.
PMID:9178344
Surface dependence: a balance control strategy in panic disorder with agoraphobia.
No top-level findings curated for this source.
PMID:9284865
A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments.
No top-level findings curated for this source.
PMID:33849246
The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Agoraphobia · 2026-09-07T15:00:13Z · View source

Created kb/disorders/Agoraphobia.yaml (MONDO:0003709), claimed via issue #11335. Coverage preflight: confirmed uncovered at origin/main eedf9251c. MONDO:0003709 appeared in kb/ only inside differential_diagnoses blocks of Panic_Disorder and Social_Anxiety_Disorder, never as a disease_term, has_subtypes term, or mondo_mappings entry. The MONDO parent MONDO:0003699 (phobic disorder) is likewise uncurated, so no parent-term entry already covered the concept. No stub, no other open claim issue among the 151 checked. Deep research: a claude_code run produced a report whose cited PMIDs all resolve and are on topic, unlike the sibling run for Intermittent Explosive Disorder. It was still treated as leads only: every reference cited here was re-located through the PubMed E-utilities API, every snippet was verified against the local cache, and every ontology term was resolved independently through OLS. The report's vestibular/space-and-motion strand was the useful contribution, since it is agoraphobia-specific rather than borrowed from panic disorder. Content: two parallel mechanistic strands converging on situational avoidance. The GLRB strand runs from non-coding glycine receptor beta subunit variation, through increased startle reflex and fear-network activation, to agoraphobic cognitions. The spatial-orientation strand runs from vestibular dysfunction, through a compensatory non-vestibular (proprioceptive/visual) balance control strategy demonstrated as surface dependence on posturography, to space and motion discomfort. Four phenotypes, one genetic susceptibility entry, a polygenic inheritance block, one animal model, three differential diagnoses, two treatments. Named entity discipline: the dominant risk for this entry is that most agoraphobia literature is conducted in panic disorder samples with agoraphobia as a modifier. Evidence was selected preferentially where the source reports an agoraphobia-specific outcome, phenotype or sample. Where it does not, that is annotated: the antidepressant treatment carries directness: INDIRECT because the quoted sentence reports the panic-attack outcome rather than the agoraphobia outcome, and the exposure-plus-antidepressant treatment carries a notes: line stating that the meta-analysis population is panic disorder with or without agoraphobia rather than agoraphobia alone. Two MONDO ids for the differential diagnoses were initially written from memory and were caught by the pre-edit term validation hook before the file was ever written: MONDO:0004746 is myopathy of extraocular muscle, not social phobia, and MONDO:0004994 is cardiomyopathy, not specific phobia. They were replaced with MONDO:0001247 and MONDO:0012000, both resolved through OLS. The Partial Glrb knockout mouse is recorded with fidelity: LOW and an explicit limitations statement: the human association is with non-coding regulatory variants while the model is a partial knockout, and agoraphobia is defined by situational cognitions about escape and help availability that have no faithful murine counterpart, so the reported agoraphobic phenotype is an avoidance-behavior analogue. Validation: just validate passes, 25/25 snippets verified against cached references, just validate-terms passes, and check-entity-refs, check-causal-targets, check-duplicate-keys, check-qualifier-terms and check-enum-values all pass.

Claude Code ▸
Agoraphobia: Comprehensive Disease Characteristics Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 41 citations 2026-09-07T14:38:39.804146

Agoraphobia: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Agoraphobia is an anxiety/fear-related disorder characterized by marked, disproportionate fear or anxiety triggered by exposure to a range of situations in which escape might be difficult or help unavailable if panic-like or other incapacitating/embarrassing symptoms occur. Since DSM-5, agoraphobia is diagnosed as an independent nosological entity, no longer subordinate to or automatically coupled with panic disorder, although the two frequently co-occur ("Panic Disorder and Agoraphobia," NCBI StatPearls, PMID reference NBK554387). Affected individuals actively avoid the triggering situations, endure them with intense distress, or require a companion to face them.

Key identifiers: - MONDO: MONDO:0003709 - Disease Ontology: DOID:593 - ICD-10: F40.0 (F40.00 without panic disorder history, F40.01 with panic disorder) - ICD-11: 6B02 (Agoraphobia) — in ICD-11, agoraphobia and panic disorder can be coded separately and comorbidly; the ICD-10 "with/without panic disorder" qualifiers have been eliminated (Kazlauskas et al., "Taxonomy of anxiety disorders—a comparison of ICD-10 and ICD-11," PMC12638383) - DSM-5-TR: 300.22 - MeSH: D000379 - HPO: HP:0000756 (Agoraphobia)

Synonyms: Fear of open spaces; fear of public places; fear of crowds; agoraphobia without history of panic disorder; panic disorder with agoraphobia (a related but now separately-coded comorbid presentation).

Data provenance: Most available information is derived from aggregated disease-level resources — large population epidemiological surveys (e.g., National Comorbidity Survey Replication, National Epidemiologic Survey on Alcohol and Related Conditions), clinical trial registries, twin/family registries (e.g., Virginia Twin Registry), and case-control neuroimaging/genetic cohorts — rather than individual EHR-level curation, reflecting the nature of psychiatric epidemiology.

Sources: - Agoraphobia - StatPearls - NCBI Bookshelf - Taxonomy of anxiety disorders—a comparison of ICD-10 and ICD-11 - PMC - Table 3.10, Panic Disorder and Agoraphobia Criteria Changes DSM-IV to DSM-5 - NCBI Bookshelf

2. Etiology

Disease Causal Factors

Agoraphobia is a multifactorial, polygenic psychiatric condition arising from an interaction of genetic vulnerability (fear-circuit and neurotransmitter-system genes), early developmental/environmental exposures (childhood adversity, parenting style), temperament (behavioral inhibition, anxiety sensitivity, neuroticism), and precipitating stressors (often an initial unexpected panic attack or a vestibular/medical event) that lead to conditioned avoidance learning. There is no known infectious or classic single-gene causal factor; it is not a Mendelian disorder.

Genetic Risk Factors

  • Heritability: Twin studies from the Virginia Twin Registry estimated heritability at ~39% in women and ~37% in men for agoraphobia; a large study of >5,000 twins reported heritability of 0.36 for agoraphobia without panic disorder history; other estimates (fears/phobias, corrected for unreliability) reach as high as 67%. DSM-5-TR cites heritability "remarkably high at 61%." Genetic factors are estimated to explain 30–60% of individual differences in phobic fears/agoraphobia across studies.
  • Source: Heritability of Self-reported Phobic Fear - PMC; Genetics of Anxiety and Trauma-Related Disorders - PMC
  • TMEM132D — the most replicated candidate gene for panic disorder with agoraphobia, first identified via GWAS at the Max Planck Institute of Psychiatry. Risk haplotype SNPs rs7309727 and rs11060369 (intron 3) were replicated across independent European-ancestry cohorts, reaching P = 1.1–1.4 × 10⁻⁸ in primary panic disorder subsets (PMID:22948381, Translational Psychiatry, "Replication and meta-analysis of TMEM132D gene variants in panic disorder"). Carriers of the risk variant show higher trait anxiety and larger amygdala volumes (PMID:24495968). TMEM132D methylation mediates the relationship between physical abuse and panic disorder risk (PMC9403743). Mouse studies support TMEM132D as a genuine anxiety-phenotype gene (Molecular Psychiatry, "TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies," PMID via nature.com/articles/mp201041).
  • GWAS findings (2023–2025): The largest genome-wide association meta-analysis of panic attacks/panic disorder to date (>277,970 individuals) identified 4 genome-wide-significant loci for panic attacks and 1 for panic disorder, with SNP-based heritability of panic disorder estimated at 6.6% (95% CI 5.7–7.6%) assuming 5% population prevalence (ScienceDirect, "Genome-wide association meta-analyses of panic disorder and panic attacks," 2024). A broader Psychiatric Genomics Consortium (PGC)-Anxiety GWAS of major anxiety disorders (122,341 European-ancestry cases, 729,881 controls) identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support, with 51/58 replicating in an independent sample of >1 million self-reported cases; follow-up analyses implicated GABAergic signaling as a key mechanistic pathway (Nature Genetics, 2025, s41588-025-02485-8). A disorder-specific large-scale GWAS from PGC-Anxiety specifically dissecting panic disorder, agoraphobia, and panic attacks is in progress/recently reported (ScienceDirect S0924977X25006200).
  • Genetic overlap: GWAS of panic disorder reveals genetic overlap with neuroticism and depression (Molecular Psychiatry, PMID s41380-019-0590-2).
  • HLA association: TMEM132D variants associate with panic disorder specifically in HLA-DRB1*13:02-negative individuals in a Japanese population (PMC4766370), suggesting gene-gene/immunogenetic interaction.
  • Family studies: Family history of panic disorder is associated with panic disorder with agoraphobia in offspring, but "agoraphobia without panic disorder did not show a familial association" in some cohort analyses (StatPearls NBK554387), suggesting partially distinct genetic architectures for the pure agoraphobia phenotype versus panic-comorbid agoraphobia.

HGNC/gene suggestions: TMEM132D (hgnc:25467, chromosome 12q24.33).

Environmental Risk Factors

  • Childhood adversity: Lack of parental warmth, parental overprotectiveness, childhood fears/night terrors, early-life grief/bereavement, unhappy or traumatic childhood, maltreatment, or sexual abuse increase risk of pathologic anxiety and agoraphobia (StatPearls NBK554387; Psychology Today; ScienceDirect topic overview).
  • Parental style: Controlling, overprotective parenting and modeling of parental anxious/fearful behavior increase risk.
  • Stressful life events: Death of a parent, being attacked or mugged, and other acute stressors are associated with onset; being raised in a household with low warmth and high overprotection is a described risk factor.
  • Precipitating medical/physiological events: An initial unexpected panic attack, or a vestibular insult (e.g., inner-ear disorder, benign paroxysmal positional vertigo, labyrinthitis) can trigger the fear-and-avoidance cascade that develops into agoraphobia (PMID:2809581, "Vestibular dysfunction followed by panic disorder with agoraphobia"; PMID:8599398, "Panic, agoraphobia, and vestibular dysfunction").
  • Sex: Female sex is a strong risk marker (see epidemiology).
  • Personality: Neuroticism, low extraversion, anxiety sensitivity, and avoidant/dependent personality traits.

Protective Factors

  • Secure attachment and parental warmth in childhood are protective against anxiety disorder development (inferred from the inverse of the childhood-adversity risk literature above).
  • Early identification and CBT-based indicated prevention programs (e.g., "Coping Cat") reduce incident anxiety symptoms in at-risk children, with effect sizes around 0.66 at 3-month follow-up (PMC5236072).
  • No specific protective genetic variant or protective allele has been robustly identified for agoraphobia specifically in GWAS to date; broader anxiety GWAS protective/susceptibility architecture is polygenic rather than driven by single protective alleles.

Gene-Environment Interactions

Childhood trauma and adverse childhood experiences interact with genetic variants such as COMT Val158Met and MAOA to influence adult anxiety sensitivity and pathologic worry (search synthesis from Psychology Today / ScienceDirect topic reviews). TMEM132D promoter/gene-body methylation mediates the effect of physical abuse exposure on panic disorder risk, illustrating an epigenetic gene-by-environment mechanism (PMC9403743, "The mediating role of transmembrane protein 132D methylation in predicting the occurrence of panic disorder in physical abuse").

Sources: - Replication and meta-analysis of TMEM132D gene variants in panic disorder - Higher anxiety and larger amygdala volumes in carriers of a TMEM132D risk variant - TMEM132D methylation mediates panic disorder risk in physical abuse - PMC - Genome-wide association study of major anxiety disorders - Nature Genetics - Genome-wide association meta-analyses of panic disorder and panic attacks - ScienceDirect - Vestibular dysfunction followed by panic disorder with agoraphobia - PubMed

3. Phenotypes

Behavioral / Symptom Phenotypes (with suggested HP terms)

Phenotype Description Suggested HPO term
Agoraphobia (core) Marked fear/anxiety in ≥2 of 5 situation clusters: public transportation, open spaces, enclosed spaces, standing in line/crowds, being outside home alone HP:0000756 Agoraphobia
Situational avoidance Active avoidance of feared situations related to HP:0000722 (Compulsive behaviors) is not exact; best captured under HP:0000756 with temporality/clinical_course qualifiers
Panic attacks Discrete episodes of intense fear with somatic symptoms (palpitations, sweating, trembling, dyspnea, choking sensation, chest pain, nausea, dizziness, derealization, fear of dying/losing control) HP:0025269 (Panic attack)
Anticipatory anxiety Anxious apprehension prior to encountering feared situations HP:0000739 (Anxiety)
Dependence on companion ("safety behavior") Requiring another person present to tolerate feared situations free-text / behavioral phenotype
Space and motion discomfort Disorientation/discomfort in visually complex or unstable environments (e.g., supermarket aisles, escalators) related to vestibular symptoms; no precise HPO term — candidate free text
Derealization/depersonalization Feeling of unreality or detachment during exposure HP:0031466 (Derealization) if present in HPO, else free text

Phenotype Characteristics

  • Age of onset: Median onset age ~20 years; onset before age 55 is typical, though a bimodal pattern is described with a second peak in later adulthood, often following a medical event (StatPearls; therecoveryvillage.com statistics compilation).
  • Severity: Variable — ranges from mild situational avoidance to complete homebound status in severe cases.
  • Progression: Typically chronic and persistent without treatment; DSM-5-TR explicitly characterizes the natural course as "persistent and chronic," with complete remission "rare" absent intervention (StatPearls NBK554387). Spontaneous remission without treatment occurs in as few as ~10% of cases.
  • Course pattern: Often episodic/fluctuating with waxing-waning severity tied to stressors, but a substantial proportion follow a chronic-relapsing course. A Harvard/Brown Anxiety Research Project longitudinal cohort (n=309) found only a 0.17 probability of full remission at 1 year for panic disorder with agoraphobia (versus 0.39 for uncomplicated panic disorder), and relapse after remission occurred rapidly (PMID:10678311, "Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up").
  • Frequency/prevalence among affected individuals: ~90% of individuals with agoraphobia have a comorbid psychiatric condition (other anxiety disorders, depressive disorders, PTSD, or alcohol use disorder) (StatPearls NBK554387).

Quality of Life Impact

Agoraphobia is associated with substantial functional impairment: decreased work productivity, increased disability days, reduced likelihood of marriage when onset is early, and in severe cases complete inability to leave the home. Long-term disability studies of anxiety disorders (PMC4950589) document sustained impairment in occupational and social functioning. Comorbidity substantially worsens quality-of-life outcomes and prognosis.

Sources: - Agoraphobia - StatPearls - Remission and relapse in subjects with panic disorder and panic with agoraphobia - PubMed - Long-term disability in anxiety disorders - PMC

4. Genetic/Molecular Information

Agoraphobia is a polygenic, complex-trait psychiatric disorder rather than a monogenic disease; there is no single causal gene analogous to a Mendelian disorder, no OMIM phenotype-gene entry, and no defined pathogenic-variant classification akin to ClinVar ACMG/AMP tiers for a rare disease.

  • Candidate/risk gene: TMEM132D (HGNC gene; 12q24.33) — the best-replicated panic-disorder/agoraphobia-associated locus, identified via GWAS and replicated across independent European and Japanese cohorts (PMID:22948381; PMC4766370). Functional/expression studies in mouse hippocampus and human peripheral blood support a role in anxiety-related gene expression (mp201041).
  • Polygenic architecture: SNP-based heritability for panic disorder ~6.6% from the 2024 GWAS meta-analysis (>277,970 individuals), with 4 genome-wide significant loci for panic attacks and 1 for panic disorder. The broader 2025 PGC-Anxiety GWAS (122,341 cases) found 58 independent genome-wide significant loci and 66 high-confidence genes across anxiety disorders broadly, implicating GABAergic signaling pathways.
  • Variant frequency/population databases: As a polygenic trait, individual variant allele frequencies (gnomAD, 1000 Genomes) are relevant only in the aggregate polygenic-risk-score sense; no single pathogenic allele has population-frequency significance analogous to monogenic disease variants.
  • Somatic vs. germline: Not applicable — agoraphobia is not a somatic/oncologic condition; all genetic risk is germline/heritable polygenic risk.
  • Functional consequences: TMEM132D risk variants are associated with quantitative trait differences — larger amygdala volume and higher trait anxiety in carriers (PMID:24495968) — and with altered emotional processing in cingulate, frontal cortex, and hippocampus circuits (referenced PMID:25974322, "Association of TMEM132D with cingulate, frontal cortex and hippocampal emotional processing in panic disorder").
  • Epigenetics: TMEM132D DNA methylation status mediates the relationship between childhood/adult physical abuse exposure and panic disorder occurrence (PMC9403743) — a concrete gene × environment epigenetic mechanism.
  • Modifier genes: COMT (Val158Met) and MAOA genotypes are reported to interact with childhood trauma/ACEs to modulate adult anxiety sensitivity and worry, functioning as modifiers of environmental risk rather than primary causal variants.
  • Chromosomal abnormalities: No recurrent copy-number variant or chromosomal syndrome is established as causally linked to agoraphobia specifically (distinguishing it from many other HPO-annotated psychiatric phenotypes that arise secondarily in syndromic conditions).

Suggested HGNC/gene annotation: TMEM132D (hgnc:25467).

Sources: - Replication and meta-analysis of TMEM132D gene variants in panic disorder - Translational Psychiatry - Polymorphisms in the TMEM132D region are associated with panic disorder in HLA-DRB1*13:02-negative individuals - PMC - TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies - Molecular Psychiatry - Genome-wide association study of major anxiety disorders - Nature Genetics

5. Environmental Information

  • Toxins/pollution/occupational exposures: No well-established specific environmental toxin or occupational exposure is documented as a direct cause of agoraphobia in the literature surveyed; this contrasts with the psychosocial/developmental environmental factors that dominate the etiological literature.
  • Lifestyle factors: Alcohol and sedative misuse frequently develop secondarily as self-medication for agoraphobic anxiety, and comorbid alcohol use disorder is common and associated with increased chronicity (Anxiety and Alcohol Use Disorders: Comorbidity and Treatment Considerations, PMC3860396). Caffeine and other sympathomimetic/panicogenic substances (e.g., stimulants) can precipitate panic symptoms that reinforce avoidance behavior.
  • Psychosocial/developmental environmental factors (see Etiology, Section 2): childhood adversity, parental overprotection/anxious modeling, stressful life events, bereavement, assault/mugging.
  • Infectious agents: Not applicable — agoraphobia has no established infectious etiology, though acute vestibular infections (e.g., viral labyrinthitis) can serve as a precipitating medical trigger for the fear-avoidance cascade in susceptible individuals (see vestibular dysfunction literature, Section 6).

Sources: - Anxiety and Alcohol Use Disorders: Comorbidity and Treatment Considerations - PMC - Vestibular dysfunction followed by panic disorder with agoraphobia - PubMed

6. Mechanism / Pathophysiology

Ordered Causal Chain (numbered mechanistic sequence)

  1. Genetic/epigenetic predisposition (e.g., TMEM132D risk haplotype; polygenic GABAergic-pathway risk variants; TMEM132D promoter methylation altered by early-life abuse) leads to heightened baseline reactivity of the amygdala-centered fear network — demonstrated in human genetic-imaging association studies; the downstream causal step from genotype to circuit change is correlational/inferred rather than experimentally proven in humans.
  2. Constitutively reduced serotonergic (5-HT) tone and diminished GABA_A receptor binding in the amygdala (particularly basolateral nucleus) results in loss of GABAergic-dependent inhibitory/compensatory restraint on amygdala output — supported directly in a mouse genetic model of brain serotonin deficiency showing facilitated panic-like escape behavior (PMC5682603), and by human PET/imaging findings of lower GABA_A and 5-HT receptor binding in the amygdala of panic disorder patients (Translational Psychiatry systematic review, PMC11258274/PMID via s41398-024-02966-0); translation from rodent to human amygdala circuitry is inferred by analogy.
  3. This disinhibited amygdala, together with dysregulated brainstem CO2/chemoreceptor ("suffocation alarm") circuitry, leads to a hypersensitive threshold for triggering the intrinsic fear/panic response — Klein's false suffocation alarm theory, refined over 30 years of research, is now considered well-established: "it is now well established that anomalies in respiratory control (including the CO2 sensing system) are key to PD"; amygdala-driven apnea has been proposed as the proximate chemoreceptive trigger (ScienceDirect S0301051122000473).
  4. Activation of this hypersensitive fear network results in engagement of the broader "fear network" — amygdala, hippocampus, thalamus, hypothalamus, periaqueductal gray, locus coeruleus, insula, anterior cingulate and prefrontal cortex, and bed nucleus of the stria terminalis — causing the acute somatic/autonomic panic attack (tachycardia, dyspnea, sweating, trembling, derealization) via noradrenergic locus coeruleus outflow and HPA-axis (CRH-ACTH-cortisol) activation — neuroimaging/neuroanatomical model, well supported across multiple systematic reviews (Alpha Psychiatry, PMC12231371/PMC12638... ; PMID:23168129 "The role of the amygdala in the pathophysiology of panic disorder: evidence from neuroimaging studies").
  5. Repeated or a single intensely aversive unexpected panic attack, occurring in a specific situational context (crowd, open space, public transit, or following a vestibular insult), leads to classical/Pavlovian interoceptive and situational fear conditioning, in which previously neutral situational and internal bodily cues become conditioned fear stimuli — supported by translational rodent fear-conditioning paradigms showing amygdala activation to conditioned stimuli (PMC3551953) and by clinical observation that agoraphobic avoidance maps onto situations where panic previously occurred or escape/help would be limited.
  6. Conditioned fear of situational/interoceptive cues results in anticipatory anxiety and hypervigilant monitoring for bodily sensations (interoceptive amplification), which leads to cognitive misappraisal of benign somatic sensations as dangerous (catastrophic misinterpretation) — supported by fMRI interoception studies in panic disorder with agoraphobia (PMC5465291) showing altered insula/interoceptive processing, and by cognitive models underlying CBT.
  7. This misappraisal and anticipatory anxiety drives deliberate avoidance of, or endurance with dread of, the trigger situations (public transportation, open spaces, enclosed spaces, crowds/lines, being away from home alone) — the behavioral hallmark of agoraphobia — resulting in progressive negative reinforcement: avoidance reduces short-term anxiety, which reinforces further avoidance and situational generalization (behavioral learning theory; not itself a "biological" mechanism but the operant loop that converts an acute panic event into a chronic phobic disorder).
  8. In parallel/contributing branch: vestibular system dysfunction (subclinical or overt) leads to an atypical, vision/proprioception-dependent balance-control strategy ("surface dependence") causing discomfort in visually complex or spatially ambiguous environments (space and motion discomfort), which compounds situational avoidance independent of, or synergistic with, the panic-conditioning pathway — demonstrated in patients with panic disorder plus moderate-to-severe agoraphobia showing the highest prevalence of vestibular abnormalities among anxiety-disorder groups (PMID:18653552; PMID:9178344 "Surface dependence: a balance control strategy in panic disorder with agoraphobia"); resting-state fMRI shows lower functional connectivity in vestibular-limbic (insula-limbic) networks even in subclinical agoraphobia (PMC6701404).
  9. Chronic activation of this fear/avoidance system leads to structural/functional brain changes over the disease course — smaller amygdala lateral/basal nuclei volumes, altered prefrontal-amygdala connectivity, and (in more severe/longer-duration illness with agoraphobia) reduced pituitary volume reflecting sustained HPA-axis engagement — resulting in the chronic, often treatment-refractory clinical phenotype seen in longstanding agoraphobia (PMC6221356 "Smaller volumes in the lateral and basal nuclei of the amygdala in patients with panic disorder"; pituitary-volume finding from ScienceDirect S0278584610004203). This step is correlational cross-sectional imaging evidence, not a demonstrated causal progression within individual patients over time.

Molecular Pathways

  • Serotonergic (5-HT) signaling — reduced brain serotonin synthesis facilitates panic-like escape behavior in genetic mouse models (PMC5682603); a novel perifornical-hypothalamic-area-projecting serotonergic system normally inhibits innate panic and conditioned fear responses (PMC10811332).
  • GABAergic signaling — implicated both mechanistically (lower GABA_A receptor binding in amygdala) and genetically (GABAergic signaling highlighted by the 2025 PGC-Anxiety GWAS as a top biological pathway).
  • Noradrenergic signaling — locus coeruleus hyperactivity/dysregulation is central to acute panic symptom generation (PMID:2258377, "Noradrenergic function in panic disorder"; ScienceDirect S0006322399002462).
  • CRH/HPA-axis signaling — corticotropin-releasing hormone modulates amygdala activity and interacts with glutamate, dopamine, serotonin, and norepinephrine systems in panic pathophysiology.
  • CCK (cholecystokinin) signaling — CCK-4 (the C-terminal tetrapeptide of cholecystokinin) reliably and dose-dependently induces panic attacks in both patients with panic disorder and healthy volunteers, indistinguishable from spontaneous attacks (PMID:2180549), and activates amygdala circuitry on fMRI (PMID:18095276), establishing CCK signaling as a validated pharmacological panic-induction pathway.
  • GO term suggestions: GO:0007268 (chemical synaptic transmission), GO:0007204 (positive regulation of cytosolic calcium ion concentration — CCK receptor signaling), GO:0007586 (digestion; CCK context is separate but the peptide signaling term is GO:0038188 cholecystokinin receptor signaling pathway if available), GO:0042493 (response to drug), GO:0006836 (neurotransmitter transport), GO:0007212 (dopamine receptor signaling pathway), GO:0007214 (gamma-aminobutyric acid signaling pathway).

Cellular Processes

Neuronal hyperexcitability in amygdala principal neurons secondary to GABAergic disinhibition; synaptic plasticity underlying conditioned fear learning (LTP-like potentiation in amygdala fear circuits); chronic stress-related processes (glucocorticoid signaling, HPA-axis feedback dysregulation).

Protein Dysfunction

No single structural protein misfolding/aggregation mechanism is implicated (unlike neurodegenerative disease); rather, receptor-level dysfunction is implicated — reduced GABA_A receptor and serotonin receptor/transporter binding density in amygdala, altered CCK receptor (CCK-B/CCKBR) sensitivity underlying panicogenic challenge responses.

Biochemical Abnormalities

Altered central GABA_A receptor binding; reduced serotonergic tone; dysregulated brainstem CO2 chemoreceptor sensitivity ("suffocation false alarm" hypersensitivity); elevated plasma cortisol at HPA-axis baseline in some panic disorder cohorts.

Immune System Involvement

An HLA association (TMEM132D effect specific to HLA-DRB1*13:02-negative individuals) suggests possible immunogenetic modulation of risk, though a primary autoimmune or chronic-inflammatory mechanism is not established for agoraphobia.

Tissue/Anatomical Mechanism Notes

See Section 7 below for detailed anatomical mapping.

Molecular Profiling

  • No disease-defining transcriptomic, proteomic, or metabolomic signature has been established specifically for agoraphobia in the literature surveyed; peripheral gene-expression profiling has been studied in the context of CCK-4-induced panic challenge (PMID:19051287, "Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects"), representing an experimental/challenge-model dataset rather than a disease-state biomarker panel.

Advanced Technologies

  • fMRI/neuroimaging (structural and functional, including resting-state connectivity) is the dominant "omics-adjacent" technology applied, with findings summarized above (amygdala volume, vestibular-limbic connectivity, interoception paradigms). Single-cell, spatial transcriptomic, and CRISPR functional-genomics data specific to agoraphobia are not established in the current literature (largely because it is a clinical/behavioral phenotype rather than a tissue-pathology disease).

Suggested CL (Cell Ontology) terms: CL:0000540 (neuron), CL:0011005 (GABAergic neuron), CL:0000850 (serotonergic neuron), CL:0000166 (chromaffin cell — HPA axis/adrenal medulla context), CL:0000162 (norepinephrine secreting cell — locus coeruleus).

Suggested UBERON/anatomical terms: UBERON:0001876 (amygdala), UBERON:0002421 (hippocampal formation), UBERON:0001897 (periaqueductal gray), UBERON:0002037 (cerebellum — vestibular pathway relay), UBERON:0002264 (insular cortex), UBERON:0002756 (locus coeruleus), UBERON:0001873 (bed nucleus of stria terminalis), UBERON:0001954 (Sylvian fissure region for prefrontal/cingulate context).

Sources: - Neurochemical and genetic factors in panic disorder: a systematic review - Translational Psychiatry - The role of the amygdala in the pathophysiology of panic disorder: evidence from neuroimaging studies - PubMed - Genetically driven brain serotonin deficiency facilitates panic-like escape behavior in mice - PMC - Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder - PubMed - Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers - PubMed - Amygdala-driven apnea and the chemoreceptive origin of anxiety - ScienceDirect - Surface dependence: a balance control strategy in panic disorder with agoraphobia - PubMed - Lower Functional Connectivity in Vestibular-Limbic Networks in Individuals With Subclinical Agoraphobia - PMC - Smaller volumes in the lateral and basal nuclei of the amygdala in patients with panic disorder - PMC

7. Anatomical Structures Affected

Organ Level

  • Primary organ: Brain (central nervous system) — specifically the limbic/fear-circuit network.
  • Secondary/systemic involvement: Cardiovascular system (tachycardia, palpitations during panic attacks), respiratory system (dyspnea, hyperventilation), vestibular/inner-ear system (balance dysfunction contributing to space-and-motion discomfort), gastrointestinal system (nausea, abdominal distress during attacks).
  • Body systems involved: Nervous system (primary), cardiovascular, respiratory, endocrine (HPA axis).

Tissue and Cell Level

  • Amygdala (particularly lateral and basal nuclei) — GABAergic and glutamatergic principal neurons.
  • Hippocampus and parahippocampal gyrus — contextual fear memory.
  • Insular cortex — interoceptive processing.
  • Locus coeruleus — noradrenergic neurons (CL:0000162).
  • Periaqueductal gray — panic/defensive behavior generation.
  • Bed nucleus of the stria terminalis — sustained/anticipatory fear vs. amygdala's phasic fear.
  • Prefrontal and anterior cingulate cortex — top-down regulation of fear response, often showing reduced regulatory engagement.
  • Vestibular nuclei/inner ear labyrinth — implicated via space-and-motion discomfort mechanism.

Subcellular Level

  • Synaptic membrane GABA_A receptor complexes (reduced binding in amygdala).
  • Serotonin transporter (SERT) and 5-HT receptors on presynaptic/postsynaptic membranes.
  • GO Cellular Component suggestions: GO:0043025 (neuronal cell body), GO:0045202 (synapse), GO:0032590 (dendrite membrane), GO:0034706 (sodium channel complex — relevant to neuronal excitability).

Localization

  • UBERON terms: amygdala (UBERON:0001876), hippocampus (UBERON:0002421), insular cortex (UBERON:0002264), locus coeruleus (UBERON:0002756), periaqueductal gray (UBERON:0001897), bed nucleus of stria terminalis (UBERON:0001873), prefrontal cortex (UBERON:0000451, frontal cortex region), pituitary gland (UBERON:0000007 — reported reduced volume with chronic illness/agoraphobia).
  • Lateralization: Findings are generally reported bilaterally, though some studies report right-lateralized amygdala volume reductions (right lateral/basal nuclei specifically, PMC6221356) and left-lateralized insula activation during anticipation of agoraphobia-specific stimuli (StatPearls neuroimaging summary).

Sources: - Smaller volumes in the lateral and basal nuclei of the amygdala in patients with panic disorder - PMC - Pituitary volume in patients with panic disorder - ScienceDirect - Lower Functional Connectivity in Vestibular-Limbic Networks - PMC

8. Temporal Development

Onset

  • Typical age: Median onset ~20 years; commonly reported range 25–30 years average; onset generally occurs before age 55. A notable proportion of first onset occurs in adolescence (12-month prevalence peaks at 2.0% in the 13–17 age group).
  • Onset pattern: Often acute/identifiable — frequently follows an initial unexpected panic attack or a discrete precipitating event (vestibular illness, assault, bereavement) — though insidious, gradually progressive onset is also described, particularly in cases arising from chronic childhood anxiety/behavioral inhibition rather than an index panic attack.

Progression

  • Disease course pattern: Chronic and persistent in the majority of untreated cases; DSM-5-TR explicitly describes the natural course as "persistent and chronic." A relapsing-remitting pattern is common even with treatment; the Harvard/Brown longitudinal cohort found rapid relapse after remission (PMID:10678311).
  • Progression rate: Variable — some patients stabilize with mild situational avoidance; others progress to severe, generalized avoidance and complete homebound status.
  • Disease duration: Typically chronic/lifelong without intervention; spontaneous remission occurs in only ~10% of untreated cases.
  • Stages: No formally staged classification system (unlike oncologic staging) exists; clinical severity is instead graded by number/breadth of avoided situations and degree of functional impairment (e.g., via the Oxford-Agoraphobic Avoidance Scale).

Patterns

  • Remission patterns: Full remission is more likely with combined CBT + pharmacotherapy; treatment-induced remission is substantially more probable than spontaneous remission. At 1-year follow-up in a naturalistic cohort, probability of full remission was only 0.17 for panic disorder with agoraphobia versus 0.39 for uncomplicated panic disorder (PMID:10678311).
  • Critical periods: Adolescence and young adulthood represent a critical window both for onset and for indicated CBT-based prevention interventions in at-risk youth (e.g., those with elevated anxiety sensitivity or behavioral inhibition).
  • Sex-based course: No significant sex difference detected in the chronicity/course of panic disorder with agoraphobia once established, despite the marked sex difference in incidence.

Sources: - Remission and relapse in subjects with panic disorder and panic with agoraphobia - PubMed - Chronicity, relapse, and illness-course of panic disorder, social phobia, and GAD - PubMed - Agoraphobia - StatPearls

9. Inheritance and Population

Epidemiology

  • 12-month prevalence: 1.7% overall; highest in ages 13–17 (2.0%); declines to 0.4% in individuals aged 65+.
  • Lifetime prevalence: 0.9% in men; 2.0% in women.
  • Agoraphobia is subsumed within the broader "anxiety disorders" category in Global Burden of Disease (GBD) estimates: globally in 2019, an estimated 45.82 million incident cases, 301.39 million prevalent cases, and 28.68 million DALYs were attributed to anxiety disorders overall (Cambridge/PMC8157816, GBD 2019 anxiety disorders analysis).

Inheritance Pattern

  • Not Mendelian. Agoraphobia follows a complex, polygenic/multifactorial inheritance pattern, consistent with heritability estimates of 36–61% from twin studies and a polygenic architecture confirmed by GWAS (58 loci for anxiety disorders broadly; 1–4 loci for panic disorder/panic attacks specifically).
  • Penetrance/expressivity: Not applicable in the Mendelian sense; risk is probabilistic and dependent on polygenic burden combined with environmental exposure (gene-environment interaction, e.g., TMEM132D methylation × abuse).
  • Genetic anticipation, germline mosaicism, founder effects, consanguinity role, carrier frequency: Not applicable / not established for this polygenic behavioral phenotype.

Population Demographics

  • Sex ratio: Marked female predominance; female-to-male prevalence ratio ranges from 1.6–3.1.
  • Affected populations / geographic distribution: Broadly distributed globally as part of the anxiety disorder spectrum; specific ethnic/geographic prevalence disparities for agoraphobia in isolation are less well characterized in the literature surveyed than for anxiety disorders overall, which show regional GBD variation.
  • Age distribution: Peak prevalence in adolescence/young adulthood, declining prevalence with advancing age (down to 0.4% at 65+), though late-onset presentations (often medically triggered) occur.

Sources: - Agoraphobia Epidemiology - News-Medical - Global, regional and national burden of anxiety disorders from 1990 to 2019: GBD 2019 - PMC - Agoraphobia - StatPearls

10. Diagnostics

Clinical Criteria (Primary Diagnostic Method)

Agoraphobia is diagnosed clinically per DSM-5-TR criteria: marked fear/anxiety about ≥2 of 5 situations (public transportation; open spaces such as parking lots/marketplaces/bridges; enclosed places such as shops/theaters; standing in line or being in a crowd; being outside the home alone), where the individual fears/avoids these situations because escape might be difficult or help unavailable if panic-like or embarrassing symptoms develop. Symptoms must persist ≥6 months and cause clinically significant distress or impairment, and cannot be better explained by another medical condition, substance use, or another mental disorder (e.g., specific phobia, social anxiety, separation anxiety, PTSD, or major depressive disorder-related avoidance).

  • ICD-11 code: 6B02; diagnosable independently of and comorbidly with panic disorder (6B01).

Screening Tools

  • GAD-7 (Generalized Anxiety Disorder-7): brief (<5 minute) self-report screening tool.
  • Oxford-Agoraphobic Avoidance Scale: self-report measure of avoidance behavior and distress across situations.

Laboratory Tests / Biomarkers

No specific validated blood, urine, or genetic biomarker exists for agoraphobia diagnosis; laboratory workup in clinical practice is typically used to rule out medical mimics (e.g., thyroid function tests to exclude hyperthyroidism, ECG/cardiac workup to exclude arrhythmia presenting with palpitations/near-syncope).

Imaging

Structural/functional MRI is a research tool (amygdala volumetrics, resting-state vestibular-limbic connectivity, fMRI interoception paradigms) rather than a diagnostic clinical requirement.

Genetic Testing

Not clinically indicated or available for agoraphobia — no gene panel, single-gene test, or chromosomal microarray is part of standard diagnostic workup, consistent with its polygenic/multifactorial nature.

Differential Diagnosis (Key Distinguishing Features)

Condition Key distinguishing feature
Specific phobia (situational type) Fear limited to a single specific situation rather than the ≥2-situation cluster of agoraphobia
Separation anxiety disorder Fear driven by detachment from attachment figures/home, not by the situations themselves
Social anxiety disorder Fear of negative judgment/scrutiny by others, not of entrapment/inability to escape
Panic disorder (without agoraphobia) Panic attacks occur without the situational avoidance/entrapment fear pattern
PTSD/acute stress disorder Avoidance tied to reminders of a specific past trauma
Major depressive disorder Avoidance due to anhedonia, low energy, or apathy rather than fear of panic/entrapment
Medical conditions (e.g., cardiac arrhythmia, vestibular/inner-ear disease, hyperthyroidism) Must be excluded as the primary driver of situational symptoms (e.g., fear of syncope from a genuine cardiovascular condition is not agoraphobia)

Sources: - Agoraphobia - StatPearls - Taxonomy of anxiety disorders—ICD-10 vs ICD-11 - PMC

11. Outcome/Prognosis

Survival and Mortality

Agoraphobia is not directly life-threatening, but it carries elevated indirect mortality risk through comorbid substance use disorder and suicide. No disease-specific survival/mortality registry data (e.g., SEER-style) exist, as is typical for non-fatal psychiatric conditions; mortality risk is mediated through comorbidities (alcohol use disorder, depression).

Morbidity and Function

  • Substantial disability: reduced work productivity, increased disability days, complete homebound status in severe untreated cases.
  • Long-term functional disability is well documented in longitudinal anxiety-disorder cohorts (PMC4950589).
  • Reduced likelihood of marriage associated with early-onset agoraphobia.

Disease Course / Complications

  • Comorbidity: ~90% have a comorbid psychiatric diagnosis; specific comorbidity rates: panic disorder 26%, major depressive disorder 12%, generalized anxiety disorder 7%, specific phobia 5%, social phobia 4%, OCD 4%, PTSD 2%.
  • Alcohol/substance use disorder: Comorbid panic disorder with agoraphobia and GAD are associated with increased risk of persistent alcohol dependence; comorbid substance use disorder significantly raises suicide-attempt risk.
  • Suicidality: Approximately 15% of individuals with agoraphobia report suicidal thoughts or behaviors.

Prognostic Factors

  • Favorable: Early identification/intervention, treatment with combined CBT + pharmacotherapy.
  • Unfavorable: Greater agoraphobia severity, presence of comorbid anxiety, depressive, personality, or substance use disorders. Without treatment, complete remission is rare (~10%).
  • No molecular/biomarker-based prognostic classifier (analogous to oncologic prognostic biomarkers) is established.

Sources: - Agoraphobia - StatPearls - Anxiety and Alcohol Use Disorders: Comorbidity and Treatment Considerations - PMC - Long-term disability in anxiety disorders - PMC

12. Treatment

Pharmacotherapy

  • First-line: SSRIs (selective serotonin reuptake inhibitors). Sertraline and escitalopram are specifically associated with higher remission rates and lower adverse-event risk (StatPearls NBK554387). Suggested CHEBI/NCIT: sertraline (CHEBI:9048), escitalopram (CHEBI:65357); NCIT treatment term NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to the specific SSRI.
  • Alternatives: SNRIs (serotonin-norepinephrine reuptake inhibitors) and tricyclic antidepressants.
  • Benzodiazepines (e.g., alprazolam): effective acutely but not preferred for long-term use due to abuse potential, sedation, cognitive dysfunction, and fall risk (StatPearls NBK554387).
  • Pharmacogenomics: No agoraphobia-specific CPIC/PharmGKB pharmacogenomic guideline exists; general SSRI pharmacogenomic considerations (e.g., CYP2C19/CYP2D6 metabolizer status affecting SSRI dosing) apply generically rather than being agoraphobia-specific.

Psychotherapy (First-Line, Often Combined with Medication)

  • Cognitive Behavioral Therapy (CBT): The first-line treatment for panic disorder and agoraphobia. Core components: psychoeducation, cognitive restructuring, breathing retraining, interoceptive exposure, and — critically — gradual in vivo exposure to overcome situational avoidance. CBT "effectively targets and alleviates primary symptoms, reduces other anxiety symptoms, and improves the patient's overall quality of life" (StatPearls). CBT results in resolution for about half of patients as monotherapy; combined CBT + pharmacotherapy offers the most effective symptomatic management.
  • NCIT suggestion: NCIT:C: — use NCIT:C15302 is Physical Therapy (not applicable); the closest general NCIT behavioral-intervention term is NCIT:C15782-type "Psychotherapy" concept, or more generically NCIT:C49236 (Therapeutic Procedure) with therapeutic_modality: BEHAVIORAL.
  • Virtual Reality Exposure Therapy (VRET): A validated modern adjunct/alternative to in-vivo exposure. Meta-analyses find VR exposure "generally as effective as in-vivo exposure" for panic disorder with agoraphobia, with "no evidence that VR exposure is significantly less efficacious than in-vivo exposure in agoraphobia" (PMC6746888, Frontiers systematic review/meta-analysis). A 2025 pilot RCT examined integrating digital/VR interventions into standard CBT for panic disorder and agoraphobia (PMID:40591874).

Experimental / Clinical Trials

  • NCT03101332 — "Virtual Reality for Panic Disorder With Agoraphobia."
  • NCT01680237 — "Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia."
  • Self-guided digital treatment with VR for panic disorder and agoraphobia — RCT protocol (PMC9123669).
  • Digital-intervention-augmented CBT pilot RCT (PMID:40591874, 2025).

Treatment Outcomes

  • CBT (in vivo exposure) and VR exposure show comparable efficacy in head-to-head meta-analyses.
  • Facing the Fear neuroimaging study examined clinical and neural effects of CBT versus pharmacotherapy in panic disorder with agoraphobia (PMID:26837851), supporting that both modalities produce measurable neurobiological change.
  • Combined CBT + SSRI/SNRI pharmacotherapy is regarded as most efficacious overall.

Treatment Strategy / Algorithm

  1. First-line: CBT with exposure component (in-vivo or VR-based).
  2. Add SSRI/SNRI pharmacotherapy for moderate-severe cases, non-response to psychotherapy alone, or patient preference.
  3. Reserve benzodiazepines for short-term/acute symptom control only, given long-term risks.
  4. Address comorbidities (depression, alcohol use disorder) concurrently given their impact on prognosis.

Sources: - Agoraphobia - StatPearls - Inferiority or Even Superiority of VRET in Phobias? Meta-Analysis - PMC - Facing the fear--clinical and neural effects of CBT and pharmacotherapy in panic disorder with agoraphobia - PubMed - Advancing CBT for panic disorder and agoraphobia by integrating a digital intervention - PubMed - Virtual Reality for Panic Disorder With Agoraphobia - ClinicalTrials.gov NCT03101332

13. Prevention

Primary Prevention

No vaccine or biological primary-prevention intervention exists. Behavioral/psychosocial primary prevention centers on reducing modifiable risk exposures: promoting parental warmth and appropriate autonomy-granting (reducing overprotection), and mitigating childhood adversity/trauma exposure where possible.

Secondary Prevention (Indicated/Selective Prevention)

  • CBT-based indicated prevention programs for children/adolescents with elevated anxiety symptoms or anxiety sensitivity (e.g., the "Coping Cat" program) reduce incident/self-reported anxiety symptoms, with an effect size of 0.66 at 3-month follow-up in a randomized controlled trial (PMC5236072).
  • Early identification of high-risk individuals (behavioral inhibition in childhood, high anxiety sensitivity, family history of panic disorder/agoraphobia) allows targeted early intervention before full syndrome development.
  • Early treatment of an index/first panic attack (before conditioned situational avoidance generalizes) is considered clinically important for preventing progression to full agoraphobia, based on the conditioning-based pathophysiological model (Section 6).

Tertiary Prevention

Ongoing CBT/exposure therapy and pharmacotherapy to prevent relapse and complication (depression, substance use disorder) in individuals with established agoraphobia; a CBT-based primary-care intervention for panic disorder showed benefit sustained to 5-year follow-up even through the COVID-19 pandemic (PMC10313059).

Screening

No population-based genetic or biomarker screening program exists; screening in practice relies on brief validated instruments (GAD-7) in primary care and mental health settings.

Public Health / Behavioral Interventions

Public mental-health literacy campaigns and school-based anxiety-prevention curricula (e.g., Coping Cat-style programs) represent the main public-health-level intervention strategy.

Sources: - Effectiveness of a CBT-Based Indicated Prevention Program for Children with Elevated Anxiety - PMC - CBT—Intervention for panic disorder in primary care: 5 years follow-up - PMC

14. Other Species / Natural Disease

Agoraphobia as a specifically-defined human DSM/ICD nosological entity has no direct veterinary disease counterpart, but closely analogous fear/anxiety behavioral syndromes are recognized in companion animals:

  • Canine and feline separation anxiety / separation-related disorder: A well-characterized behavioral disorder in dogs (and less commonly cats) involving fear/anxiety responses triggered by separation from an attachment figure, with both externalized behaviors (destruction, vocalization, house-soiling) and internalized signs (depression-like withdrawal, inappetence). Recent terminology has shifted from "separation anxiety" to "separation-related disorder/problem" to reflect that signs may represent fear, anxiety, or frank phobic behavior rather than anxiety alone (Wikipedia/veterinary literature synthesis; Today's Veterinary Practice).
  • Physiological biomarkers in dogs: Dogs diagnosed with separation-related problems show elevated salivary vasopressin concentrations upon owner separation compared to controls (PMC6941168), providing a translational neuroendocrine biomarker.
  • Comparative relevance: While canine separation-related disorder is not "agoraphobia" per se (it centers on separation from an attachment figure rather than fear of open/public spaces or entrapment), it shares core mechanistic features with human anxiety/panic-spectrum disorders — dysregulated attachment-related fear circuitry — and serves as a naturally-occurring model for comparative behavioral neuroscience and psychopharmacology (e.g., testing anxiolytics).
  • Taxonomy: Canis lupus familiaris (NCBITaxon:9615), Felis catus (NCBITaxon:9685).
  • OMIA: No specific OMIA entry for a Mendelian "agoraphobia" trait was identified in this search; separation-related disorder in dogs is understood as a complex behavioral trait rather than a single-locus Mendelian condition.
  • Zoonotic potential/cross-species transmission: Not applicable — this is a behavioral/neuropsychiatric phenotype, not an infectious disease.

Sources: - Separation anxiety in dogs - Wikipedia - Salivary Vasopressin as a Potential Non-Invasive Biomarker of Anxiety in Dogs - PMC - Algorithmic Approach: Separation Anxiety in Dogs - Today's Veterinary Practice

15. Model Organisms

Rodent Behavioral Models (Face Validity for Agoraphobia-Relevant Traits)

  • Elevated Plus Maze (EPM): Innate avoidance of open-arm exploration is argued to reflect an anxiety-like "agoraphobia" analog in rodents; reduced open-arm entry parallels human agoraphobic avoidance of open spaces.
  • Open Field Test: Reduced center-field entry and increased thigmotaxis (wall-hugging) in rodents mirror reduced center-field exploration observed in humans with high anxiety sensitivity or clinical agoraphobia, supporting cross-species translational validity of open-field paradigms.
  • Pavlovian fear conditioning: Robust behavioral/physiological conditioned-fear responses in rodents, with amygdala activation demonstrated via awake rodent fMRI during conditioned-stimulus presentation (PMC3551953) — directly modeling the situational/interoceptive fear-conditioning step of the proposed human pathophysiological chain (Section 6, step 5).
  • Conditioned operant conflict tests: Model learned/punished avoidance behavior, complementing the innate/unlearned EPM and open-field paradigms.

Genetic Mouse Models

  • Brain serotonin-deficient mice (Tph2-related constitutive serotonin synthesis deficiency): Show facilitated panic-like escape behavior, directly supporting the mechanistic role of serotonergic deficiency combined with loss of GABAergic compensatory mechanisms in the basolateral amygdala (PMC5682603, "Genetically driven brain serotonin deficiency facilitates panic-like escape behavior in mice").
  • TMEM132D mouse studies: Human-mouse translational work established TMEM132D as a genuine anxiety-phenotype gene, with mouse expression/behavioral data supporting the human GWAS association (Molecular Psychiatry, mp201041).
  • CO2/chemoreceptor models: Locus coeruleus noradrenaline depletion studies in male and female mice show differential impact on CO2-induced panic-like responses and hyperventilation, modeling the suffocation-alarm/CO2-hypersensitivity mechanism (ScienceDirect S0278584624001313) with a sex-difference dimension relevant to the strong female-predominance seen clinically.
  • Perifornical-hypothalamic-projecting serotonergic system: A specific serotonergic circuit identified in rodents that inhibits innate panic and conditioned fear responses when intact (PMC10811332), representing a mechanistic/circuit-level model with direct relevance to panic/agoraphobia pathophysiology.

Model Characteristics — Recapitulation and Limitations

  • Phenotype recapitulation: Rodent models robustly recapitulate the acute physiological panic response (autonomic activation, escape/avoidance behavior, amygdala activation) and the conditioned-fear-acquisition process central to agoraphobic avoidance learning.
  • Limitations: Rodent models cannot capture the complex cognitive/interoceptive misappraisal component (catastrophic misinterpretation of bodily sensations) that is central to human cognitive models of agoraphobia, nor the socially/situationally complex triggers (crowds, public transportation, being far from home) that define the human DSM-5 diagnostic criteria — these are behaviorally proxied (open-field thigmotaxis, EPM open-arm avoidance) rather than directly modeled. Vestibular-contribution mechanisms (space and motion discomfort) also lack a well-established rodent behavioral correlate in the literature surveyed.

Applications

Rodent EPM/open-field/fear-conditioning models are used to screen anxiolytic pharmacotherapy candidates, dissect neurocircuit-level (amygdala, locus coeruleus, serotonergic) contributions, and test CO2/respiratory-challenge and CCK-4-type panicogenic pharmacological probes preclinically before human challenge studies.

Resources

Standard model-organism resources (MGI for mouse genetics, IMPC/KOMP for knockout lines) are the relevant databases for TMEM132D and serotonergic-pathway mouse models, though this search did not identify a dedicated public repository specifically curating "agoraphobia" mouse models as a named disease category (reflecting that these are modeled as anxiety/panic-behavior phenotypes rather than as a distinct agoraphobia entity).

Sources: - Genetically driven brain serotonin deficiency facilitates panic-like escape behavior in mice - PMC - Identification of a novel perifornical-hypothalamic-area-projecting serotonergic system that inhibits innate panic and conditioned fear responses - PMC - TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies - Molecular Psychiatry - Imaging Conditioned Fear Circuitry Using Awake Rodent fMRI - PMC - Locus coeruleus noradrenaline depletion and its differential impact on CO2-induced panic and hyperventilation in male and female mice - ScienceDirect

Summary of Key Ontology Term Suggestions

Category Term ID
Disease Agoraphobia MONDO:0003709
Phenotype Agoraphobia HP:0000756
Phenotype Panic attack HP:0025269
Phenotype Anxiety HP:0000739
Gene TMEM132D hgnc:25467
GO (molecular pathway) gamma-aminobutyric acid signaling pathway GO:0007214
GO (molecular pathway) serotonin receptor signaling pathway (context-dependent GO term)
GO (cellular component) synapse GO:0045202
CL GABAergic neuron CL:0011005
CL serotonergic neuron CL:0000850
CL norepinephrine secreting cell CL:0000162
UBERON amygdala UBERON:0001876
UBERON hippocampal formation UBERON:0002421
UBERON locus coeruleus UBERON:0002756
UBERON periaqueductal gray UBERON:0001897
UBERON insular cortex UBERON:0002264
CHEBI sertraline CHEBI:9048
CHEBI escitalopram CHEBI:65357
NCIT (treatment) Pharmacotherapy NCIT:C15986
NCIT (treatment) Therapeutic Procedure (behavioral/CBT) NCIT:C49236

Notes on Evidence Gaps

  • No OMIM phenotype MIM number exists for agoraphobia (it is not modeled as a Mendelian disorder in OMIM).
  • No ClinVar/ClinGen pathogenic-variant curation applies, consistent with its polygenic architecture.
  • Orphanet does not list agoraphobia (it is a common, non-rare psychiatric disorder, outside Orphanet's rare-disease scope).
  • A disorder-specific, adequately powered GWAS isolating agoraphobia (as distinct from panic disorder/panic attacks) is still emerging as of 2025 (PGC-Anxiety disorder-specific GWAS referenced above); most current genetic evidence is either for panic disorder broadly or the combined "major anxiety disorders" phenotype, so gene-level claims specific to pure agoraphobia (without panic disorder) should be flagged as extrapolated/indirect evidence in downstream curation.
  • Model-organism literature models panic/fear-conditioning behavior rather than the specific DSM-5 situational construct of agoraphobia; any pathophysiology-to-model links should be flagged with appropriate fidelity/limitations given this scale/construct gap.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 38
Resolved 37
Unresolved (possible confabulation) 1
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 0
Quoted claims not found in source 1
References weighed for topical relevance 37
On topic 28
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • PMC:PMC12638 (1 mention) - NCBI reports no such accession in PMC

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

  • PMC:PMC6746888 (abstract only): "no evidence that VR exposure is significantly less efficacious than in-vivo exposure in agoraphobia"
  • closest text in source: "Conclusions: We found no evidence that VR exposure is significantly less efficacious than in vivo exposure in Specific Phobia and Agoraphobia"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 42
Resolved 41
Unresolved (possible confabulation) 0
Obsolete 1
Unverifiable 0
Terms whose name was checked 34
Terms named correctly 15
Terms named as a different term 12
Terms whose name is worth a second look 7

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0031466 (1 mention) - the report calls it "Derealization"; HP calls it Impairment in personality functioning
  • GO:0042493 (1 mention) - the report calls it "response to drug"; GO calls it GO_0042493
  • CL:0000166 (1 mention) - the report calls it "chromaffin cell — HPA axis/adrenal medulla context"; CL calls it chromaffin cell
  • CL:0000162 (3 mentions) - the report calls it "norepinephrine secreting cell — locus coeruleus", "Locus coeruleus — noradrenergic neurons", "norepinephrine secreting cell"; CL calls it parietal cell
  • UBERON:0001897 (3 mentions) - the report calls it "periaqueductal gray"; UBERON calls it dorsal plus ventral thalamus
  • UBERON:0002037 (1 mention) - the report calls it "cerebellum — vestibular pathway relay"; UBERON calls it cerebellum
  • UBERON:0002264 (3 mentions) - the report calls it "insular cortex"; UBERON calls it olfactory bulb
  • UBERON:0002756 (3 mentions) - the report calls it "locus coeruleus"; UBERON calls it anterior cingulate gyrus
  • UBERON:0001873 (2 mentions) - the report calls it "bed nucleus of stria terminalis"; UBERON calls it caudate nucleus
  • UBERON:0001954 (1 mention) - the report calls it "Sylvian fissure region for prefrontal/cingulate context"; UBERON calls it Ammon's horn
  • CHEBI:9048 (2 mentions) - the report calls it "sertraline"; CHEBI calls it Schisantherin A
  • CHEBI:65357 (2 mentions) - the report calls it "escitalopram"; CHEBI calls it abacopterin D

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

  • GO:0042493 (GO_0042493) (1 mention) - replaced by GO:0009410

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0007204 (1 mention) - the report calls it "positive regulation of cytosolic calcium ion concentration — CCK receptor signaling"; GO calls it positive regulation of cytosolic calcium ion concentration
  • GO:0007212 (1 mention) - the report calls it "dopamine receptor signaling pathway"; GO calls it G protein-coupled dopamine receptor signaling pathway, and lists "dopamine receptor signalling pathway" among its other names
  • CL:0011005 (2 mentions) - the report calls it "GABAergic neuron"; CL calls it GABAergic interneuron
  • UBERON:0001876 (3 mentions) - the report calls it "amygdala", "UBERON terms: amygdala"; UBERON calls it amygdala**, and lists "nucleus amygdalae" among its other names
  • GO:0034706 (1 mention) - the report calls it "sodium channel complex — relevant to neuronal excitability"; GO calls it sodium channel complex
  • NCIT:C49236 (2 mentions) - the report calls it "Therapeutic Procedure (behavioral/CBT)"; NCIT calls it Therapeutic Procedure
  • NCBITaxon:9615 (1 mention) - the report calls it "Canis lupus familiaris", "Taxonomy: *Canis lupus familiaris"; NCBITaxon calls it Canis lupus familiaris**

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • CL:0000162 - called "norepinephrine secreting cell — locus coeruleus", "Locus coeruleus — noradrenergic neurons", "norepinephrine secreting cell"
  • UBERON:0001876 - called "amygdala", "UBERON terms:** amygdala"
  • NCBITaxon:9615 - called "Canis lupus familiaris", "Taxonomy:* Canis lupus familiaris"